| 001 | 286735 | ||
| 005 | 20240301121555.0 | ||
| 024 | 7 | _ | |a 10.3233/JAD-230961 |2 doi |
| 024 | 7 | _ | |a pmid:38189757 |2 pmid |
| 024 | 7 | _ | |a 1387-2877 |2 ISSN |
| 024 | 7 | _ | |a 1875-8908 |2 ISSN |
| 037 | _ | _ | |a DKFZ-2024-00074 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Angelidou, Ioanna Antigoni |b 0 |
| 245 | _ | _ | |a Validation of the 'Perceptions Regarding pRE-Symptomatic Alzheimer's Disease Screening' (PRE-ADS) Questionnaire in the German Population: Attitudes, Motivations, and Barriers to Pre-Symptomatic Dementia Screening. |
| 260 | _ | _ | |a Amsterdam |c 2024 |b IOS Press |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1704812495_20277 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a Attitudes, motivations, and barriers to pre-symptomatic screening for Alzheimer's disease (AD) in the general population are unclear, and validated measurement tools are lacking.Translation and validation of the German version of the 'Perceptions regarding pRE-symptomatic Alzheimer's Disease Screening' (PRE-ADS) questionnaire.A convenience sample (N = 256) was recruited via an online platform. Validation of the PRE-ADS-D consisted of assessments of reliability, structural validity using Principal Component Analysis (PCA) and Exploratory Factor Analysis (EFA) and construct validity using known-group tests. A subscale 'Acceptability of Screening', with 5 PRE-ADS-D items, was extracted to measure acceptance of screening in clinical practice. The STROBE checklist was used for reporting.EFA revealed a three-factor model for the PRE-ADS-D. Acceptable to good internal consistency was found for the 25-item scale (α= 0.78), as well as for the three factors 'Concerns about Screening' (α= 0.85), 'Intention to be Screened' (α= 0.87), and 'Preventive Health Behaviors' (α= 0.81). Construct validity was confirmed for both the 25-item PRE-ADS-D and the 'Acceptability of Screening' scale (α= 0.91). Overall, 51.2% of the participants showed a preference for screening. Non-parametric tests were conducted to further explore group differences of the sample.The PRE-ADS-D is a reliable and valid tool to measure attitudes, motives, and barriers regarding pre-symptomatic dementia screening in the German-speaking general population. Additionally, the subscale 'Acceptability of Screening' demonstrated good construct validity and reliability, suggesting its promising potential as a practical tool in clinical practice. |
| 536 | _ | _ | |a 313 - Krebsrisikofaktoren und Prävention (POF4-313) |0 G:(DE-HGF)POF4-313 |c POF4-313 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de |
| 650 | _ | 7 | |a Alzheimer’s disease |2 Other |
| 650 | _ | 7 | |a attitude |2 Other |
| 650 | _ | 7 | |a biomarker |2 Other |
| 650 | _ | 7 | |a psychometrics |2 Other |
| 650 | _ | 7 | |a screening |2 Other |
| 650 | _ | 7 | |a validity |2 Other |
| 650 | _ | 2 | |a Humans |2 MeSH |
| 650 | _ | 2 | |a Motivation |2 MeSH |
| 650 | _ | 2 | |a Alzheimer Disease: diagnosis |2 MeSH |
| 650 | _ | 2 | |a Reproducibility of Results |2 MeSH |
| 650 | _ | 2 | |a Asymptomatic Diseases |2 MeSH |
| 650 | _ | 2 | |a Checklist |2 MeSH |
| 700 | 1 | _ | |a Stocker, Hannah |0 P:(DE-He78)104fae0755c89365b7ae32238b3f1f52 |b 1 |u dkfz |
| 700 | 1 | _ | |a Beyreuther, Konrad |b 2 |
| 700 | 1 | _ | |a Teichmann, Birgit |b 3 |
| 773 | _ | _ | |a 10.3233/JAD-230961 |g Vol. 97, no. 1, p. 309 - 325 |0 PERI:(DE-600)2070772-1 |n 1 |p 309 - 325 |t Journal of Alzheimer's disease |v 97 |y 2024 |x 1387-2877 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:286735 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 1 |6 P:(DE-He78)104fae0755c89365b7ae32238b3f1f52 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Krebsforschung |1 G:(DE-HGF)POF4-310 |0 G:(DE-HGF)POF4-313 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Krebsrisikofaktoren und Prävention |x 0 |
| 914 | 1 | _ | |y 2024 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b J ALZHEIMERS DIS : 2022 |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-08-25 |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-08-25 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2023-08-25 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-08-25 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2023-08-25 |
| 920 | 1 | _ | |0 I:(DE-He78)C070-20160331 |k C070 |l C070 Klinische Epidemiologie und Alternf. |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C070-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::